Formulation and Evaluation of Floating Drug Delivery System of Aceclofenac

SENGODAN TAMIZHARASI, T. SIVAKUMAR, RATHI JAGDISH CHANDRA
Department of Pharmaceutics, Nandha College of Pharmacy and Research Centre, Erode, 638 052 Tamil-Nadu, India

Abstract
A sustained release system for aceclofenac designed to increase its residence time in the stomach without contact with the mucosa was achieved through the preparation of floating microspheres by the emulsion solvent diffusion technique. Floating microspheres were prepared using either Eudragit S 100 (ES) alone or with Eudragit RL 100 in different ratios. All formulation show good flow properties. The floating microspheres were found to be spherical by SEM. FT-IR study confirmed the drug-polymer compatibility. Although aceclofenac release rate from Eudragit S 100 floating microspheres was very slow and incomplete but when Eudragit RL 100 was added, release rate increased. Formulation AP6 containing ES:ERL (1:5:0.5) which showed appropriate balance between release rate and buoyancy could be advantageous in terms of increased bioavailability of aceclofenac. Therefore data obtained suggest that floating drug delivery system produced would be an interesting gastroretentive controlled release delivery system for aceclofenac. The prepared formulation will minimize the irritant effect of aceclofenac on the stomach by avoiding direct contact with the mucosa and providing a mean of low dosage for prolonged period.

Key words:
Aceclofenac, floating microspheres, Eudragit S 100, Eudragit RL 100, emulsion solvent diffusion

How to Cite this Paper:

Copyright ©2010 IJDDR, Sengodan Tamizharasi et al. This is an open access paper distributed under the copyright agreement with Serials Publication, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article History:------------------------
Date of Submission: 06-07-2011
Date of Acceptance: 05-08-2011
Conflict of Interest: NIL
Source of Support: NONE

Introduction
Drugs that are easily absorbed from the gastrointestinal tract (GIT) and have a short half-life are eliminated quickly from the blood circulation, require frequent dosing. To avoid this problem, the oral controlled release (CR) formulations have been
developed in an attempt to release the drug slowly into the GIT and maintain a constant drug concentration in the serum for longer period of time. Such oral drug delivery devices have a restriction due to the gastric retention time (GRT), a physiological limitation. Therefore, prolonged gastric retention is important in achieving control over the GRT because this helps to retain the CR system in the stomach for a longer time in a predictable manner. Thus the real issue in the development of oral controlled release dosage form is not just to prolong the delivery of the drugs, but to prolong the presence of the dosage forms in the stomach or somewhere in the upper small intestine until all the drug is released for the desired period of time. It may improve bioavailability and reduce drug waste.

Over the last three decades, various approaches have been pursued to increase the retention of an oral dosage form in the stomach, including floatation system, bioadhesive systems, which adhere to mucosal surface, density controlled system, which either float or sink in gastric fluid, swellable delivery system, which increase in size after swelling and retard the passage through the pylorus, modified shape systems, magnetic systems, superporous hydrogel system and other delayed gastric emptying devices.

In fact, the buoyant dosage unit enhances GRT without affecting the intrinsic rate of emptying. Unfortunately, floating devices administered in a single-unit form such as hydrodynamically balanced system are unreliable in prolonging the GRT owing to their ‘all-or-nothing’ empty process and, thus, they may cause high variability in bioavailability and local irritation due to a large amount of drug delivered at a particular site of the GIT. While multiple unit particulate dosage form (e.g. microspheres) have the advantages that they pass uniformly through the GIT to avoid the vagaries of gastric emptying and provide an adjustable release, thereby reducing the intersubject variability in absorption and risk of local irritation. The concept of floating microspheres can also be utilized to minimize the irritant effect of weakly acidic drugs on the stomach by avoiding direct contact with the mucosa and providing a mean of getting low dosage for prolonged periods.

The object of the present investigation is to develop floating drug delivery system of aceclofenac to minimize the irritant effect of drug on the stomach by avoiding direct contact with the mucosa and providing a mean of low dosage for prolonged period. Aceclofenac is a novel NSAID indicated for the symptomatic treatment of pain and inflammation. The mean plasma elimination half life is 4 h. The side effect is dyspepsia, abdominal pain, diarrhea, nausea, dizziness, and gastric constipation. To reduce the dosing frequency and adverse effect during prolong treatment, it is needed to formulate aceclofenac in long acting dosage form.

MATERIAL AND METHODS

Materials

Aceclofenac was received as a gift sample from Aristo Pharmaceutical Pvt Ltd (Mandideep, India). Eudragit S 100 and Eudragit RL 100 were purchased from Rohm Pharma (Darmstadt, Germany. Ethanol was obtained from Sakthi Sugar Pvt Ltd (Erode, India). Dichloromethan and sodium lauryl sulphate was purchased from S.D. Fine Chem. Ltd (Mumbai, India). All other chemicals were of analytical grade.

Preparation of floating microspheres of aceclofenac

Floating microspheres containing aceclofenac were prepared using emulsion-solvent diffusion technique. The drug to polymer ratio used to prepare the different formulations was as shown in table 1. The drug polymer mixture dissolved in a mixture of ethanol (8 mL) and dichloromethan (8 mL) was dropped into 0.2% sodium lauryl sulfate solution (400 ml). The solution was stirred with a propeller-type agitator at room temperature for 1 h at 500 rpm. The formed floating microspheres were filtered, washed with water and dried at room temperature in a desicator.

Aceclofenac is a novel NSAID indicated for the symptomatic treatment of pain and inflammation. The mean plasma elimination half life is 4 h. The side effect is dyspepsia, abdominal pain, diarrhea, nausea, dizziness, and gastric constipation. To reduce the dosing frequency and adverse effect during prolong treatment, it is needed to formulate aceclofenac in long acting dosage form.

MATERIAL AND METHODS

Materials

Aceclofenac was received as a gift sample from Aristo Pharmaceutical Pvt Ltd (Mandideep, India). Eudragit S 100 and Eudragit RL 100 were purchased from Rohm Pharma (Darmstadt, Germany. Ethanol was obtained from Sakthi Sugar Pvt Ltd (Erode, India). Dichloromethan and sodium lauryl sulphate was purchased from S.D. Fine Chem. Ltd (Mumbai, India). All other chemicals were of analytical grade.

Preparation of floating microspheres of aceclofenac

Floating microspheres containing aceclofenac were prepared using emulsion-solvent diffusion technique. The drug to polymer ratio used to prepare the different formulations was as shown in table 1. The drug polymer mixture dissolved in a mixture of ethanol (8 mL) and dichloromethan (8 mL) was dropped into 0.2% sodium lauryl sulfate solution (400 ml). The solution was stirred with a propeller-type agitator at room temperature for 1 h at 500 rpm. The formed floating microspheres were filtered, washed with water and dried at room temperature in a desicator.
Table 4. Formulation of preliminary trials of Eudragit floating microspheres.

<table>
<thead>
<tr>
<th>S.N.</th>
<th>Formulation Code</th>
<th>Drug : Polymer</th>
<th>Accelofenac (gm)</th>
<th>Eudragit S 100 (gm)</th>
<th>Eudragit RL 100 (gm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>AP₁</td>
<td>1</td>
<td>0.5</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>AP₂</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>AP₃</td>
<td>1</td>
<td>2</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>AP₄</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>AP₅</td>
<td>1</td>
<td>1.75</td>
<td>0.25</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>AP₆</td>
<td>1</td>
<td>1.5</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>AP₇</td>
<td>1</td>
<td>1.25</td>
<td>0.75</td>
<td></td>
</tr>
</tbody>
</table>

**Micromeritic properties**

The microspheres were characterized by their micrometric properties, such as particle size, true density, tapped density, compressibility index (% CI: a value useful in prediction of flowability), porosity and flow properties. The particle size was measured using an optical microscope and the mean particle size was calculated by measuring around 200 particles with the help of a calibrated ocular micrometer. The tapping method was used to determine the tapped density and percentage compressibility index as follows.

Tapped density = Mass of floating microspheres / Volume of floating microspheres after tapping

% Compressibility index = \([1-V/V₀] \times 100\)

Where \(V\) and \(V₀\) are the volumes of the sample after and before the standard tapping respectively. The true density of floating microspheres was determined by liquid displacement method using n-hexane as solvent\(^{21}\). Porosity (\(ε\)) of the floating microspheres was calculated using the following equation\(^{22}\).

\[ε = \left[1 - \frac{P_t}{P_p}\right] \times 100\]

Where \(P_t\) and \(P_p\) are the true density and tapped density respectively. Angle of repose (\(θ\)) of the floating microspheres, which measures the resistance to particle flow, was determined by a fixed funnel method and calculated as

\[\tan θ = \frac{2H}{D}\]

where \(2H/D\) is the surface area of the free standing height of the microspheres heap that is formed on a graph paper after making the microspheres flow from the glass funnel.

**Scanning electron microscopy**

The floating microspheres were examined for surface morphology and shape using scanning electron microscope (Jeol JSM – 5610, Japan). Samples were fixed on carbon tape and fine gold sputtering was applied in a high vacuum evaporator. The acceleration voltage was set at 20KV during scanning. Microphotographs were taken on different magnification.

**Drug entrapment and yield of floating microspheres**

The floating microspheres containing drug were dissolved in a mixture of dichloromethane and ethanol (1:1 v/v) by ultrasonication. The dissolved drug amount was measured by UV-spectrophotometer (UV-1601 Shimadzu, Japan) at 274 nm after suitable dilution. No interference was found due to the other components at 274 nm. Drug entrapment and yield were calculated as follows.

% Drug entrapment = Calculated drug concentration / Theoretical drug concentration \times 100

% Yield = [ Total weight of floating microspheres / Total weight of drug and polymer ] \times 100

**Fourier transform infra-red spectroscopy (FT-IR) analysis**

The FT–IR analysis was conducted for the analysis of drug polymer interaction and stability of drug during microencapsulation process. Fourier transform infra-red spectrum of pure aceclofenac, Eudragit S 100, Eudragit RL 100 and floating microspheres were...
recorded using FT–IR spectrophotometer (IR-470, Shimadzu, Japan).

In vitro evaluation of floating ability
Fifty milligrams of the floating microspheres were placed in 0.1 N HCl (100 mL) containing 0.02% Tween 20. The mixture was stirred at 100 rpm in a magnetic stirrer. The layer of buoyant microspheres was pipetted and separated by filtration at 1, 2, 4 and 8 hours. The collected microspheres were dried in a desiccator over night. The percentage of floating microspheres was calculated by the following equation: %Floating microspheres = (Weight of floating microspheres / Initial weight of floating microspheres) x 100

In vitro release studies
The drug release rate from floating microspheres was carried out using the USP dissolution paddle assembly (Elico Lab, Mumbai). A weighed amount of floating microspheres equivalent to 100 mg drug were dispersed in 900 mL of 0.1 N HCl (pH 1.2) maintained at 37 ± 0.5°C and stirred at 100 rpm. At preselected time intervals sample was withdrawn. The collected samples were suitably diluted with 0.1 N HCl and analysed spectrophotometrically at 274 nm. The initial volume of the dissolution fluid was maintained by adding same volume of fresh dissolution fluid after each withdrawal. The dissolution studies were repeated using phosphate buffer pH 6.8 as dissolution medium. All the previous experiment were done in triplicate

Kinetic modeling of drug release
The dissolution profile of all the batches was fitted to zero-order, first order, Higuchi models to ascertain the kinetic modeling of drug release.

RESULTS AND DISCUSSION

Micromeric properties
The particle size was determined by optical microscopy. The particle size of floating microspheres plays important role in floating ability and release character of drug from microspheres. Smaller the microspheres floating ability will be less and faster will be the release rate of the drug from the microspheres, while larger the size, floating ability will be more and sustained will be the release of drug. In Eudragit microspheres the mean particle size of microspheres was increased with the increasing Eudragit S 100 concentration. The viscosity of the medium increase at a higher polymer concentration resulting in enhanced interfacial tension. Shearing efficiency is also diminished at higher viscosities, result in the formation of larger particles. The mean size was influenced by the content and type of Eudragit used and its ratio in the formulation. The mean particle size ranged from 273.7 ± 17.55 to 355.08 ± 13.41 for Eudragit S 100 (table 2). The tapped density values ranged from 0.415 ± 0.005 to 0.439 ± 0.01 g/cm³, while their true density ranged between 0.714 ± 0.022 to 0.748 ± 0.017 g/cm³ of all the formulations obviously, the density values of the floating microspheres were less than that of the gastric fluid (∼1.004 g/cm³) thereby, employing that these floating microspheres will have the propensity to exhibit an good buoyancy effect in vivo. The porosity of all the formulations was found to be in the range of 39.38 ± 1.52 – 45.43 ± 1.54%. All formulation showed excellent flowability as represented in terms of angle of repose. Percentage compressibility value ranged between 14.43 ± 1.38 to 18.34 ± 2.32% suggested excellent flowability of floating microspheres (table 1).

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Mean particle size* (µm)</th>
<th>True density* (g/cm³)</th>
<th>Tapped density* (g/cm³)</th>
<th>Compressibility index* %</th>
<th>Porosity*</th>
<th>Angle of repose* (°)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AP₁</td>
<td>273.70±17.55</td>
<td>0.714±0.022</td>
<td>0.415 ± 0.005</td>
<td>14.43 ± 1.38</td>
<td>43.57±1.12</td>
<td>28°76' ± 0.78'</td>
</tr>
</tbody>
</table>

Table 1 : Micromeritics properties of different floating microspheres

Covered in Index Copernicus with IC Value 4.68 for 2010

Covered in Scopus & Embase, Elsevier
Morphology

Scanning electron microscopic photographs of floating microspheres are shown in fig. 1 (A to D). Floating microspheres were spherical with no visible major surface irregularity. Few wrinkles and inward dents were appeared at the surface. It may be due to the collapse of the floating microspheres during the in situ drying process. Formulation formed entirely of ES 100 were observed to be fairly spherical, sphericity was decreasing when the content of Eudragit RL 100 increased. The surface morphology of floating microspheres was examined at higher magnifications (fig 1 C & D), which illustrate the smooth surface of floating microspheres. Some small pores and cavities were present on the surface of floating microspheres, probably arising as a trace of solvent evaporation during the process.

<table>
<thead>
<tr>
<th>Formulation</th>
<th>AP₂</th>
<th>AP₃</th>
<th>AP₄</th>
<th>AP₅</th>
<th>AP₆</th>
<th>AP₇</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>310.33 ± 13.97</td>
<td>338.87 ± 10.29</td>
<td>355.08 ± 13.41</td>
<td>319.47 ± 15.24</td>
<td>303.89 ± 8.65</td>
<td>293.14 ± 19.15</td>
</tr>
<tr>
<td></td>
<td>0.723 ± 0.016</td>
<td>0.743 ± 0.026</td>
<td>0.748 ± 0.017</td>
<td>0.744 ± 0.023</td>
<td>0.738 ± 0.024</td>
<td>0.729 ± 0.034</td>
</tr>
<tr>
<td></td>
<td>0.422 ± 0.011</td>
<td>0.432 ± 0.006</td>
<td>0.439 ± 0.01</td>
<td>0.425 ± 0.005</td>
<td>0.420 ± 0.006</td>
<td>0.418 ± 0.009</td>
</tr>
<tr>
<td></td>
<td>15.34 ± 1.89</td>
<td>16.62 ± 1.67</td>
<td>17.32 ± 1.23</td>
<td>16.48 ± 2.12</td>
<td>18.34 ± 2.32</td>
<td>17.34 ± 1.45</td>
</tr>
<tr>
<td></td>
<td>41.43 ± 1.78</td>
<td>39.68 ± 1.73</td>
<td>39.38 ± 1.52</td>
<td>42.4 ± 1.43</td>
<td>43.45 ± 1.54</td>
<td>45.43 ± 1.54</td>
</tr>
<tr>
<td></td>
<td>31°54’ ± 0.65</td>
<td>33°45’ ± 0.92</td>
<td>32°21’ ± 1°82’</td>
<td>34°65’ ± 0.59’</td>
<td>38°46’ ± 0.82’</td>
<td>40°07’ ± 0.53’</td>
</tr>
</tbody>
</table>

Figure 1. Scanning electron microphotographs of Eudragit floating microspheres. (A and B) lower magnification (C and D) higher magnification

Drug entrapment and yield of floating microspheres

The entrapment efficiency of the drug depended on the solubility of the drug in the solvent and continuous phase. An increase in the concentration of polymer in a fixed volume of organic solvent resulted in an increase in entrapment efficiency. Notably, in case of Eudragit S 100 microspheres, the entrapment efficiencies of the microspheres prepared with Eudragit S 100 were higher than those of microspheres prepared with the Eudragit S/RL combination. The drug retained decreased with the increase in Eudragit RL 100 content of floating microparticle. This could be due to the permeation characteristics of this polymer that could facilitate the diffusion of a part of entrapped drug to the surrounding medium during preparation of floating microspheres. The entrapment efficiencies ranged from 64.78 ± 1.76% to 79.12 ± 2.85% for Eudragit S microspheres. The percentage yield of different formulations was determined by weighing the floating microspheres after drying. In preliminary trial, the percentage
yield of different formulations for Eudragit S 100 was in the range of from 60.25 ±1.63 to 79.55 ± 0.96. In general, percentage yield was increasing with increased concentration of Eudragit S 100 up to a certain concentration than deceased but on adding Eudragit RL 100, percentage yield was increased.

Fourier transform infrared spectroscopy (FT-IR) analysis

The FT-IR spectra of the aceclofenac, polymer, physical mixture of drug - polymer and formulated floating microspheres were recorded. Pure aceclofenac showed 3319.7, 2971.0, 2937.5, 1835.6, 1772.0, 1749.1, 1717.5, 1583.6, 1508.3, 1362.0, 1271.6, and 669.3 wave number as major peaks due to C=O stretching, OH stretching CH stretching superimposed on OH stretching, NH stretching and C-Cl respectively. In Eudragit S 100 microspheres, The characteristic peaks due to pure aceclofenac appeared at 3319.9, 2972.1, 2937.5, 1835.6, 1772.1, 1748.5, 1717.6, 1583.9, 1508.4, 1366.2, 1271.6, and 670, without any markable change in their position after successful encapsulation, indicating no chemical interaction between aceclofenac, Eudragit S 100 and Eudragit RL 100. It also confirmed the stability of drug during microencapsulation process.

In vitro evaluation of floating ability

The purpose of preparing floating microspheres was to extend the GRT of the drug. The floating ability test was carried out to investigate the floatability of the prepared microspheres. The floating test was carried out to investigate the floatability of the prepared microspheres in 0.1 N HCl (pH 1.2) containing 0.02 % Tween 20. Tween 20 was added to counteract the downward pulling at the liquid surface by lowering surface tension.

In Eudragit floating microspheres, the floating ability pattern differed according to the formulation tested and the medium used suggesting interplay between various factors. In preliminary trial, formulation AP$_6$ gave the best floating ability as evidenced by the percentage of particles floated at different time intervals (Table 4). Although the formulation contains a percentage of the permeable ERL, yet the surface of floating microspheres is regular. This would decrease points of contact and therefore the opportunity of aggregate formation upon hydration. The floating properties of microspheres may be attributed to the low bulk density and the porosity of the floating microspheres, implying that the floating microspheres will have the propensity to exhibit an excellent buoyancy effect in vivo. Stirring speed had negative effect on the floating ability. This may be due to decreasing the particle size of floating microspheres on increasing the stirring speed.

In vitro drug release study

In vitro dissolution studies of aceclofenac from floating microspheres were performed in 0.1 N HCl (pH 1.2) and pH 6.8 for 12 hours using USP dissolution test apparatus I. It was found that formulations AP$_1$ showed 42.83±0.77 release while AP$_4$ showed of 27.89±1.032 release in 0.1N HCl in 12 hours.. Eudragit S100 polymer, which is present in all formulations, is of low permeability and insoluble in acid medium. It is an anionic copolymer of methacrylic acid, methyl methacrylate...
containing free carboxylic and ester groups. It’s very low permeability results from high intermolecular attraction between its molecules. Hydrogen bonding between the hydroxyl groups of the carboxylic moiety and the carbonyl oxygen of ester groups increase the degree of compactness of the polymer and decrease its porosity and permeability. Because of these characters, drug release rate from floating microspheres prepared only by Eudragit S 100 was very slow and incomplete in 0.1 N HCl. The rate of drug release from the microspheres depended on the polymer concentration of the prepared devices, which indicates that the release rate decrease with increasing the amount of the polymer.

Table 2: Percentage yield and entrapment drug content of floating microspheres.

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Percentage yield* (%)</th>
<th>Drug entrapment* (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AP₁</td>
<td>61.24 ±1.71</td>
<td>64.78 ±1.76</td>
</tr>
<tr>
<td>AP₂</td>
<td>64.8 ±2.38</td>
<td>69.78 ±1.07</td>
</tr>
<tr>
<td>AP₃</td>
<td>68.07±3.81</td>
<td>76.94 ±2.14</td>
</tr>
<tr>
<td>AP₄</td>
<td>60.25 ±1.63</td>
<td>79.12 ±2.85</td>
</tr>
<tr>
<td>AP₅</td>
<td>71.99 ±1.52</td>
<td>76.94 ±2.14</td>
</tr>
<tr>
<td>AP₆</td>
<td>79.04 ±0.6</td>
<td>73.18± 2.81</td>
</tr>
<tr>
<td>AP₇</td>
<td>79.55 ± 0.96</td>
<td>67.09 ±2.14</td>
</tr>
</tbody>
</table>

* Average of three preparation ± S.D.

On the other hand, ERL is a copolymer of acrylic and methacrylic acid esters with a low content of quaternary ammonium groups. The ammonium groups present as salts give rise to permeability and act, after their dissolution, as channeling agents for the entrance of the dissolution medium through the floating microparticle wall causing its swelling. This gives an opportunity for the dissolved drug to diffuse out to the bulk medium. To increase drug release considerably, the more quantity of Eudragit RL 100 was added to achieve further drug release. For formulations AP₅, AP₆ and AP₇, the drug release was 36.68±1.37% to 50.96±1.81% in 12 hours. The results obtained at pH 6.8 showed a different trend. While the formulation formed of ES100 only, showed the least amount released in 0.1 N HCl, it gave an appreciable release in buffer pH 6.8. ES100 is an enteric coating material. So, it will start to dissolve at pH 6.8 due to ionization of carboxylic acid groups, thus allowing penetration of solvent and liberation of the drug. Formulation AP₁ gave 99.25 ± 1.53% release and AP₄ gave 78.55 ± 1.69% release in pH 6.8, while from formulation AP₅ to AP₇ showed a mixed effect due to the presence of two different types of Eudragit. Both the high degree of hydration of ERL leading to formation of hydrated channels, associated with the dissolution of ES100, determined the release of drug at pH 6.8. Formulation AP₅ to AP₇ gave 86.58 ± 2.11% to 97.14 ± 2.76 % drug releases.

Comparative cumulative % drug release profiles of formulations AP₁ to AP₇ in pH 1.2

Comparative cumulative % drug release profiles of formulations AP₁ to AP₇ in pH 6.8
Table 3: Percentage floating of different formulations of floating microspheres in 0.1 N HCl (ph 1.2) containing 0.02 % Tween 20

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>1 hrs*</th>
<th>2 hrs*</th>
<th>4 hrs*</th>
<th>8 hrs*</th>
</tr>
</thead>
<tbody>
<tr>
<td>AP1</td>
<td>88.31±1.13</td>
<td>85.67±1.45</td>
<td>80.87±1.93</td>
<td>64.53±3.78</td>
</tr>
<tr>
<td>AP2</td>
<td>94.62±1.81</td>
<td>91.89±2.12</td>
<td>83.78±1.23</td>
<td>69.32±1.58</td>
</tr>
<tr>
<td>AP3</td>
<td>97.54±1.32</td>
<td>92.43±1.45</td>
<td>88.34±1.56</td>
<td>75.30±2.27</td>
</tr>
<tr>
<td>AP4</td>
<td>98.32±1.42</td>
<td>96.54±1.78</td>
<td>92.55±2.13</td>
<td>80.97±3.78</td>
</tr>
<tr>
<td>AP5</td>
<td>96.43±0.98</td>
<td>93.67±1.98</td>
<td>89.13±1.86</td>
<td>72.22±2.83</td>
</tr>
<tr>
<td>AP6</td>
<td>98.78±0.43</td>
<td>95.43±1.76</td>
<td>92.87±2.87</td>
<td>80.64±1.89</td>
</tr>
<tr>
<td>AP7</td>
<td>92.72±2.24</td>
<td>87.53±1.65</td>
<td>82.65±2.87</td>
<td>68.15±3.10</td>
</tr>
</tbody>
</table>

Kinetic modeling

The release data of formulations were fitted to models representing zero order, first-order and Higuchi’s square-root of time model to predict the drug release kinetics and mechanism. The release constant was calculated from the slope of appropriate plots, and the regression coefficient (r²) was determined. It was found that the in-vitro drug release of floating microspheres was best explained by zero order kinetic as the plots showed the highest linearity and it indicated a time-independent release process.

CONCLUSION

Gastro-retentive floating microspheres have emerged as an efficient means of enhancing the bioavailability and controlled delivery of many drugs. The present formulation study of aceclofenac was performed in an attempt to prepare floating drug delivery system of floating multiple unit system using emulsion-solvent diffusion technique and the performance of these formulations was evaluated. The ideal properties of floating microspheres are a high buoyancy and sufficient release of drugs in pH 6.8 solution. In developing a desired intragastric floating system employing these microspheres, it is necessary to select an appropriate balance between buoyancy and drug releasing rate and formulation AP6 showed the best appropriate balance between buoyancy and drug release rate.

The designed system AP6 combining high buoyant ability and suitable drug release rate, could possibly be advantageous in terms of increased bioavailability of aceclofenac. The designed system AP6 might be able to float in the stomach. This phenomenon could prolong the gastric residence time (GRT) and delay drug arrival at the absorption site; consequently, the sustained action provided, in addition, floating microspheres enabled increased drug absorption rate of drug as the floating microspheres in the stomach gradually sank and arrived at the absorption site. Same time the prepared formulation will minimize the irritant effect of aceclofenac on the stomach by avoiding direct contact with the mucosa and providing a mean of low dosage for prolonged period. Therefore, multiple unit floating system, i.e, floating microspheres should be possibility beneficial with subject to sustain action. The developed formulation overcomes and alleviates the drawbacks and limitations of sustained release preparations. Major advantages of the prepared formulations include:

- Easy of Preparation
- Good Buoyancy
- Sustained Release Over Several Hours.

REFERENCES

2. Singh BN, Kim KH. Floating drug delivery system: an approach to oral controlled


